Skip to main content
Clinical Trials/NCT04524715
NCT04524715
Withdrawn
Not Applicable

Low-Level Laser Therapy Treatment of Lung Inflammation in COVID-19 Patients

Ward Photonics LLC1 site in 1 countryJuly 31, 2021
ConditionsCovid19

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Covid19
Sponsor
Ward Photonics LLC
Locations
1
Primary Endpoint
Inflammation of the lungs - CRP
Status
Withdrawn
Last Updated
3 years ago

Overview

Brief Summary

To determine if a reduction of pneumonic inflammation occurs after treatment with Low-Level Laser Therapy (LLLT) applying red-light technology in the respiratory system of COVID-19 patients suffering from acute viral pneumonia.

Detailed Description

This clinical trial is a blinded before and after comparison of the effect on patients treated with a red-light LLLT therapy for acute lung inflammation as a result of COVID-19 infection. Patients are enrolled to undergo LLLT therapy in addition to all standard ongoing therapies for COVID-19. Outcomes for patients receiving LLLT in addition to their standard care (the treatment group) are compared to the group receiving only standard therapy for COVID-19 (control group). Effects of LLLT treatment are measured immediately following treatment, and outcome measurements are compared to the pre-treatment baseline.

Registry
clinicaltrials.gov
Start Date
July 31, 2021
End Date
March 31, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participant is diagnosed with COVID-
  • Study participant is 18 years of age or older.
  • Patient exhibiting moderate-to-acute respiratory distress.

Exclusion Criteria

  • Photosensitive condition or medication.
  • Active chemotherapy treatment or other cancer treatment.
  • Autoimmune Disorder.
  • Pregnant, possibly pregnant or planning pregnancy prior to the end of study participation.
  • Developmental disability or cognitive impairment that, in the opinion of the investigator, would preclude adequate comprehension of the informed consent form and/or ability to record the necessary study measurements.

Outcomes

Primary Outcomes

Inflammation of the lungs - CRP

Time Frame: 10 days

Change in inflammation of the lungs as measured by C-Reactive Protein (CRP) Test

Inflammation of the lungs - IL6

Time Frame: 10 days

Change in inflammation of the lungs as measured by IL-6 Levels

Inflammation of the lungs - O2

Time Frame: 10 days

Change in inflammation of the lungs as measured by O2 saturation levels

Study Sites (1)

Loading locations...

Similar Trials